Last reviewed · How we verify
V114 1x:1x:2x — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
V114 1x:1x:2x (V114 1x:1x:2x) — Merck Sharp & Dohme LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| V114 1x:1x:2x TARGET | V114 1x:1x:2x | Merck Sharp & Dohme LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- V114 1x:1x:2x CI watch — RSS
- V114 1x:1x:2x CI watch — Atom
- V114 1x:1x:2x CI watch — JSON
- V114 1x:1x:2x alone — RSS
Cite this brief
Drug Landscape (2026). V114 1x:1x:2x — Competitive Intelligence Brief. https://druglandscape.com/ci/v114-1x-1x-2x. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab